Emerging Functions for ANKHD1 in Cancer-related Signaling Pathways and Cellular Processes

Overview

Journal BMB Rep

Specialties Biochemistry
Molecular Biology

Date 2020 Jul 9

PMID 32635985

Citations 6

Authors

Bruna Oliveira de Almeida

Joao Agostinho Machado-Neto

Affiliations

Soon will be listed here.

Abstract

ANKHD1 (ankyrin repeat and KH domain containing 1) is a large protein characterized by the presence of multiple ankyrin repeats and a K-homology domain. Ankyrin repeat domains consist of widely existing protein motifs in nature, they mediate protein-protein interactions and regulate fundamental biological processes, while the KH domain binds to RNA or ssDNA and is associated with transcriptional and translational regulation. In recent years, studies containing relevant information on ANKHD1 in cancer biology and its clinical relevance, as well as the increasing complexity of signaling networks in which this protein acts, have been reported. Among the signaling pathways of interest in oncology regulated by ANKHD1 are Hippo signaling, JAK/STAT, and STMN1. The scope of the present review is to survey the current knowledge and highlight future perspectives for ANKHD1 in the malignant phenotype of cancer cells, exploring biological, functional, and clinical reports of this protein in cancer. [BMB Reports 2020; 53(8): 413-418].

Citing Articles

Upregulating ANKHD1 in PS19 mice reduces Tau phosphorylation and mitigates Tau-toxicity-induced cognitive deficits.

Tian X, Le N, Zhao Y, Alawamleh D, Schwartz A, Meyer L bioRxiv. 2024; .

PMID: 39605390 PMC: 11601383. DOI: 10.1101/2024.11.15.623890.

Nuclear Import and Export of YAP and TAZ.

Kofler M, Kapus A Cancers (Basel). 2023; 15(20).

PMID: 37894323 PMC: 10605228. DOI: 10.3390/cancers15204956.

Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines.

Saar M, Jaal J, Meltsov A, Laasfeld T, Lust H, Kasvandik S Pharmaceutics. 2023; 15(5).

PMID: 37242727 PMC: 10221650. DOI: 10.3390/pharmaceutics15051485.

Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling.

Werner J, Bernhard P, Cosenza-Contreras M, Pinter N, Fahrner M, Pallavi P Neoplasia. 2023; 36:100871.

PMID: 36610378 PMC: 9841175. DOI: 10.1016/j.neo.2022.100871.

MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.

Matuszyk J Mol Med. 2022; 28(1):89.

PMID: 35922756 PMC: 9351108. DOI: 10.1186/s10020-022-00516-2.

References

Sedgwick S, Smerdon S . The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci. 1999; 24(8):311-6. DOI: 10.1016/s0968-0004(99)01426-7. View

Traina F, Favaro P, de Souza Medina S, Duarte A, Winnischofer S, Costa F . ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. Biochim Biophys Acta. 2006; 1762(9):828-34. DOI: 10.1016/j.bbadis.2006.07.010. View

Nicastro G, Taylor I, Ramos A . KH-RNA interactions: back in the groove. Curr Opin Struct Biol. 2015; 30:63-70. DOI: 10.1016/j.sbi.2015.01.002. View

Smith R, Carroll P, Allard J, Simon M . MASK, a large ankyrin repeat and KH domain-containing protein involved in Drosophila receptor tyrosine kinase signaling. Development. 2002; 129(1):71-82. DOI: 10.1242/dev.129.1.71. View

Sidor C, Brain R, Thompson B . Mask proteins are cofactors of Yorkie/YAP in the Hippo pathway. Curr Biol. 2013; 23(3):223-8. DOI: 10.1016/j.cub.2012.11.061. View

Muller P, Kuttenkeuler D, Gesellchen V, Zeidler M, Boutros M . Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature. 2005; 436(7052):871-5. DOI: 10.1038/nature03869. View

Valverde R, Edwards L, Regan L . Structure and function of KH domains. FEBS J. 2008; 275(11):2712-26. DOI: 10.1111/j.1742-4658.2008.06411.x. View

Machado-Neto J, Campos P, Favaro P, Lazarini M, Lorand-Metze I, Costa F . Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leuk Res. 2013; 38(2):251-7. DOI: 10.1016/j.leukres.2013.11.013. View

Yu F, Zhao B, Guan K . Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015; 163(4):811-28. PMC: 4638384. DOI: 10.1016/j.cell.2015.10.044. View

10.

Fisher K, Fragiadaki M, Pugazhendhi D, Bausek N, Arredondo M, Thomas S . A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability. J Cell Sci. 2018; 131(13). PMC: 6051347. DOI: 10.1242/jcs.209551. View

11.

Machado-Neto J, Lazarini M, Favaro P, Franchi Jr G, Nowill A, Olalla Saad S . ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014; 324(2):137-45. DOI: 10.1016/j.yexcr.2014.04.004. View

12.

Miles M, Janket M, Wheeler E, Chattopadhyay A, Majumder B, DeRicco J . Molecular and functional characterization of a novel splice variant of ANKHD1 that lacks the KH domain and its role in cell survival and apoptosis. FEBS J. 2005; 272(16):4091-102. DOI: 10.1111/j.1742-4658.2005.04821.x. View

13.

Machado-Neto J, Lazarini M, Favaro P, Campos P, Scopim-Ribeiro R, Franchi Junior G . ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. Biochim Biophys Acta. 2014; 1853(3):583-93. DOI: 10.1016/j.bbamcr.2014.12.012. View

14.

Zhou Z, Jiang H, Tu K, Yu W, Zhang J, Hu Z . ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1):18. PMC: 6332640. DOI: 10.1186/s13046-018-1011-0. View

15.

Liu X, Han Q, Rong X, Yang M, Han Y, Yu J . ANKHD1 promotes proliferation and invasion of non‑small‑cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway. Int J Oncol. 2020; 56(5):1175-1185. PMC: 7115354. DOI: 10.3892/ijo.2020.4994. View

16.

Kitamata M, Hanawa-Suetsugu K, Maruyama K, Suetsugu S . Membrane-Deformation Ability of ANKHD1 Is Involved in the Early Endosome Enlargement. iScience. 2019; 17:101-118. PMC: 6606961. DOI: 10.1016/j.isci.2019.06.020. View

17.

Islam Z, Nagampalli R, Fatima M, Ashraf G . New paradigm in ankyrin repeats: Beyond protein-protein interaction module. Int J Biol Macromol. 2017; 109:1164-1173. DOI: 10.1016/j.ijbiomac.2017.11.101. View

18.

Duarte A, Traina F, Favaro P, Basseres D, de Carvalho I, de Souza Medina S . Characterisation of a new splice variant of MASK-BP3(ARF) and MASK human genes, and their expression patterns during haematopoietic cell differentiation. Gene. 2005; 363:113-22. DOI: 10.1016/j.gene.2005.08.002. View

19.

Fragiadaki M, Zeidler M . Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs. J Biol Chem. 2018; 293(25):9570-9579. PMC: 6016471. DOI: 10.1074/jbc.RA117.000975. View

20.

Yang C, Zheng J, Liu X, Xue Y, He Q, Dong Y . Role of ANKHD1/LINC00346/ZNF655 Feedback Loop in Regulating the Glioma Angiogenesis via Staufen1-Mediated mRNA Decay. Mol Ther Nucleic Acids. 2020; 20:866-878. PMC: 7256448. DOI: 10.1016/j.omtn.2020.05.004. View